Boston type 1 keratoprosthesis: Updated perspectives
© 2020 Nonpassopon et al. The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved b...
Saved in:
Main Authors: | , , |
---|---|
Format: | Journal |
Published: |
2020
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084201039&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70958 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-70958 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-709582020-10-14T08:45:35Z Boston type 1 keratoprosthesis: Updated perspectives Manachai Nonpassopon Muanploy Niparugs Maria Soledad Cortina Medicine © 2020 Nonpassopon et al. The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implan-tation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management. 2020-10-14T08:45:35Z 2020-10-14T08:45:35Z 2020-01-01 Journal 11775483 11775467 2-s2.0-85084201039 10.2147/OPTH.S219270 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084201039&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70958 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Chiang Mai University Library |
collection |
CMU Intellectual Repository |
topic |
Medicine |
spellingShingle |
Medicine Manachai Nonpassopon Muanploy Niparugs Maria Soledad Cortina Boston type 1 keratoprosthesis: Updated perspectives |
description |
© 2020 Nonpassopon et al. The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implan-tation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management. |
format |
Journal |
author |
Manachai Nonpassopon Muanploy Niparugs Maria Soledad Cortina |
author_facet |
Manachai Nonpassopon Muanploy Niparugs Maria Soledad Cortina |
author_sort |
Manachai Nonpassopon |
title |
Boston type 1 keratoprosthesis: Updated perspectives |
title_short |
Boston type 1 keratoprosthesis: Updated perspectives |
title_full |
Boston type 1 keratoprosthesis: Updated perspectives |
title_fullStr |
Boston type 1 keratoprosthesis: Updated perspectives |
title_full_unstemmed |
Boston type 1 keratoprosthesis: Updated perspectives |
title_sort |
boston type 1 keratoprosthesis: updated perspectives |
publishDate |
2020 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084201039&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70958 |
_version_ |
1681752997491638272 |